ICON and DIA driving Insights to Action with DIA Live 2019
DIA Live combines powerful AI analysis and data visualisation features of news and social media conversations at DIA Global Annual Meeting.
ICON’s Acquisition of MeDiNova Research
The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.
ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research
ICON Wins Multiple Awards at the 2019 Clinical and Research Excellence Awards
ICON Launches New Patient Engagement Platform to Support Improved Patient Experience & Enrolment in Clinical Trials
Increasing visibility of potential study participants to sites and sponsors.
ICON Reports First Quarter 2019 Results
Net business wins (including pass-through) in the quarter of $885 million; a book to bill of 1.31.
Forbes names ICON one of the best employers in America
ICON ranked top CRO in anonymous survey of 50,000 employees across 38 sectors
ICON wins multiple categories in 2019 CRO Leadership Awards
ICON recognised for specialised services offering across product development lifecycle
ICON Acquires MolecularMD
ICON enhances it molecular diagnostic testing services, a key area in oncology research, with it's acquisition of MolecularMD.
ICON Reports Fourth Quarter and Full Year 2018 Results
Full year reported revenue was $2,595.8 million. Excluding the impact of ASC 606, full year revenue increased to $1,897.6 million from $1,758.4 million in 2017, an increase of 7.9%.
ICON Launches New Drug Safety Reporting Solution Ensuring Compliance Through Automation
Developed on platform deploying rule-based automation for timely delivery of drug safety information.